2005 Annual report - Virbac

31
❖ Equine
Equine products closed the year up 6.2%, in particular thanks
to the launch of Equimax ® in France (broad-spectrum wormer
for horses) and the introduction of new packaging in other
countries.
❖ Specialised petfood
In 2005, this business continued to gain market share, rising
by 2.1% on 2004. This change is down to the growth of the
Virbac Vet Complex ® range in France in a market that is growing
at veterinary clinics, but also the launch of the range in
Japan, Korea, Spain and New Zealand.
❖ Electronic identification
Following spectacular growth in 2004, this segment saw a
decline in sales in 2005 of –13.2% at constant exchange
rates. This business had enjoyed a one-off impulse in 2004
from the discovery of a case of canine rabies in southwest
France, which had driven owners to identify their animals.
Food producing animals
This business accounts for 32.5% of Group sales and grew
by 2.2% at constant exchange rates in 2005.
❖ Bovine parasiticides
This range was down 4.4% on 2004 following the decision
of the US subsidiary to pull out of the generic bovine
parasiticides market in the US.
Major events during the year:
- the launch of a full range of bovine parasiticides
(ivermectin-based parasiticides) in France at the end
of September 2005,
- the launch of Virbamec ® F (bovine parasiticide)
in the United Kingdom and Spain.
❖ Other bovine products
These products grew 5.7% in 2005 with strong performance
across the whole business. In Europe, the Shotapen ®
antibiotic (antibiotic against bovine respiratory complaints)
which was re-registered with the regulatory authorities in
2004, performed extremely well. In Australia, growth largely
stemmed from the sales generated under a distribution
agreement with Intervet.
❖ Pig and poultry antibiotics
Following a decline in 2004, this segment grew by 1.5% in
2005 with performance varying between regions. A decline
in Europe apart from Greece, strong growth in South Africa
where the subsidiary performed very well on the back of
sales of Pulmodox ® POS (oral antibiotic for the treatment of
respiratory infections in pigs), recovery in Asia following
a decline in 2004.
❖ Other pig and poultry products
These products declined slightly.
Breakdown of sales by segment
Specialty/Range Sales Growth per segment
(€ millions) > -5% -5% to 0% 0% to +5% +5% to +10% +10% to +15% > 15%
Companion animals 234.3 7.5%
Parasiticides 47.6 17.8%
Immunology 46.4 5.5%
Antibiotics/Dermatology 36.9 3.4%
Specialities 41.9 12.2%
Equine 22.3 6.2%
Specialised petfood 13.8 2.1%
Others 25.4 -2.1%
Food producing animals 121.4 2.2%
Bovine parasiticides 20.6 -4.4%
Other bovine products 62.1 5.7%
Pig and poultry antibiotics 32.0 1.5%
Other pig and poultry products 6.7 -4.0%
Other business activities 16.7 -8.3%